Cover Image
市場調查報告書

異合子家族性高膽固醇血症 (heFH):開發中產品分析

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361635
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
異合子家族性高膽固醇血症 (heFH):開發中產品分析 Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 35 Pages
簡介

異合子家族性高膽固醇血症 (heFH)是遺傳性疾病,來自家長一方受影響的FH的突變引起。症候有黃色瘤,角膜弓,主動脈破裂和末稍血管疾病等。危險因素有年齡,性別,抽煙,高血壓,有相關性的脂質異常(譬如低的HDLC水平,高TG水平或類型III異脂蛋白血症的存在)等。

本報告提供異合子家族性高膽固醇血症 (heFH) 治療藥的開發情形的相關調查,開發中產品的概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等。

簡介

  • 調查範圍

異合子家族性高膽固醇血症 (heFH)的概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Daewoong Co Ltd
  • Gemphire Therapeutics Inc
  • Merck & Co Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9360IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H1 2017, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.

Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 2, 2, 1 and 1 respectively.

Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Heterozygous familial hypercholesterolemia (heFH) - Overview
    • Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development
    • Daewoong Co Ltd
    • Gemphire Therapeutics Inc
    • Merck & Co Inc
  • Heterozygous familial hypercholesterolemia (heFH) - Drug Profiles
    • (atorvastatin calcium + ezetimibe) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anacetrapib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gemcabene calcium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGL-3196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGL-3745 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects
  • Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products
  • Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2017: Madrigal Pharmaceuticals Provides Update on lead compound MGL-3196
      • Feb 23, 2017: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia
      • Nov 28, 2016: Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia
      • Jan 14, 2014: Merck Voluntarily Recalls All Lots of LIPTRUZET in the United States From Wholesalers Due to Packaging Defects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Daewoong Co Ltd, H1 2017
  • Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Gemphire Therapeutics Inc, H1 2017
  • Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Merck & Co Inc, H1 2017
  • Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, H1 2017
  • Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top